<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01818856</url>
  </required_header>
  <id_info>
    <org_study_id>LLC-TEL-2012-1</org_study_id>
    <secondary_id>2012-002515-25</secondary_id>
    <nct_id>NCT01818856</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Interactions Between Telaprevir and Un-boosted Atazanavir</brief_title>
  <official_title>Pharmacokinetic Interactions Between Telaprevir and Un-boosted Atazanavir in HIV/HCV-co-infected Patients Under Treatment for Genotype 1 Chronic Hepatitis C.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospitales Universitarios Virgen del Rocío</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospitales Universitarios Virgen del Rocío</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: the Telaprevir(TVR) plasma levels (750 mg q8h or 1125 mg/12h )will not be
      affected when co-administered with un-boosted Atazanavir (ATV) 200 mg q12h plus two analogues
      (NRTIs) in HCV/HIV-co-infected patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives

        1. Primary Outcome Measures: evaluate the changes in the plasma pharmacokinetic parameters
           (Cmax, Cmin, AUC, t 1/2, and Cl) of Telaprevir (TVR) administered at 750 mg/8h together
           with un-boosted Atazanavir (200 mg/12h), taking as reference the pharmacokinetic
           parameters observed when TVR is administered with Atazanavir/ritonavir (300/100 mg/day)

        2. To assess the changes in the plasma pharmacokinetic parameters of Atazanavir
           administered as 200 mg/12h with respect to its administration as 300/100 mg/day when
           administered together with TVR (750 mg/8h or 1125 mh/12h).

      Method: open labelled clinical trial with a planned duration of 24 weeks in which 14
      HIV/Hepatitis C virus genotype 1 patients under treatment with pegylated α-interferon,
      Ribavirin and Telaprevir will be enrolled. A 24 hours pharmacokinetic profile will be
      obtained after a supervised drug intake while taking TVR and ATV/rtv. Afterwards, the
      patients will take un-boosted ATV 200 mg bid for 7 - 10 days. Subsequently, a new
      pharmacokinetic profile will be obtained.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in pharmacokinetic parameters of TVR</measure>
    <time_frame>7 - 10 days</time_frame>
    <description>The Telaprevir peak concentrations (Cmax), trough levels (Cmin) at 8 or 12 hours, the areas under the curves over the dosing interval (AUC0-τ), and half-life during the elimination phase (t½ β) will be compared between days 0 and 7 as geometric mean ratios (GMRs) and their 90% CIs using day 0 values as reference. The differences in pharmacokinetic parameters between the regimens will be considered significant when the interval between low and high 90% CI did not include the value 1.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in pharmacokinetic parameters of ATV</measure>
    <time_frame>7 - 10 days</time_frame>
    <description>The Atazanavir peak concentrations (Cmax), trough levels (Cmin) at 12 or 24 hours, the areas under the curves over the dosing interval (AUC0-τ), and half-life during the elimination phase (t½ β) will be summarized as geometric means (GM) and will be compared between days 0 and 7 as geometric mean ratios (GMRs) and their 90% CIs using day 0 values as reference. The differences in pharmacokinetic parameters between the regimens will be considered significant when the interval between low and high 90% CI did not include the value 1.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Telaprevir interactions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telaprevir 750 mg/8h or 1125 mg/12h (+ pegIFN alfa and ribavirin) plus Atazanavir/ritonavir 300/100 mg/24. Pharmacokinetic profile on day 0.
Intervention: Ritonavir will be withdrawn and the atazanavir dose increased to 200 mg/12h for days 1 to 7. On day 8: a morning dose of Telaprevir (750 mg or 1125 mg) plus Atazanavir 200 mg. Pharmacokinetic profile for 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir withdrawal, atazanavir 200 mg/12h</intervention_name>
    <arm_group_label>Telaprevir interactions</arm_group_label>
    <other_name>Reyataz</other_name>
    <other_name>Norvir</other_name>
    <other_name>Incivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telaprevir interactions</intervention_name>
    <arm_group_label>Telaprevir interactions</arm_group_label>
    <other_name>Incivo</other_name>
    <other_name>Reyataz</other_name>
    <other_name>Norvir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years old co-infected with HIV and genotype 1 HCV under treatment
             with pegylated α-interferon, Ribavirin and Telaprevir according to the recommendations
             of the Spanish Agency of Medicines and Health Products.

          -  Informed consent of the patient.

        Exclusion Criteria:

          -  The usual exclusion criteria in clinical practice to start the treatment with these
             drugs (pegylated α-interferon, Ribavirin, Telaprevir and atazanavir) according to the
             Spanish and international recommendations (Spanish Agency of Medicines and Health
             Products,European Association for the Study of the Liver Clinical Practice Guidelines:
             management of hepatitis C virus infection. J Hepatol. 2011. Consensus Document of
             Gesida/Spanish Plan on Aids regarding the antiretroviral treatment in adults infected
             with the human immunodeficiency virus [Updated January 2012]).

          -  Concomitant use of drugs or medicinal products that could alter the pharmacokinetics
             of TVR or ATV.

          -  Medical records suggesting malabsorption or presence of diarrhea (&gt;3 depositions/day)
             that could interfere with the absorption of the studied drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis F Lopez-Cortes, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla. Spain.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Seville</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2012</study_first_submitted>
  <study_first_submitted_qc>March 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2013</study_first_posted>
  <last_update_submitted>April 19, 2013</last_update_submitted>
  <last_update_submitted_qc>April 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospitales Universitarios Virgen del Rocío</investigator_affiliation>
    <investigator_full_name>Luis F. Lopez-Cortes</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Chronic hepatitis C</keyword>
  <keyword>HIV-infection</keyword>
  <keyword>Drug interaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

